Emre Mat, İsmail Bağlar, Esra Keles, Ahmet Özkul, Lokman Tekin Ertekin
Southern Clinics of Istanbul Eurasia - 2025;36(3):224-227
Objective: The aim of this study was to evaluate the success rate of ectopic pregnancy cases treated with single-dose methotrexate in an advanced gynecology and obstetrics center over a 10-year period and the factors affecting the response to treatment. Methods: A total of 120 patients who were diagnosed with ectopic pregnancy and treated with single dose systemic methotrexate between January 2014 and December 2024 were retrospectively included in the study. Demographic data, clinical findings, baseline beta-hCG levels, treatment responses, and rates of conversion to surgery if necessary were analyzed. Results: In the study, treatment success with a single dose of methotrexate was 78.3%. The rate of second dose methotrexate administration was 13.3% and the rate of surgical requirement was 8.3%. Baseline beta-hCG level was found to be the most important factor affecting treatment success (p<0.001). Conclusion: Single-dose methotrexate treatment is an effective and safe treatment option in cases of ectopic pregnancy with appropriate criteria. Careful patient selection based on baseline beta-hCG level and ectopic mass characteristics may increase treatment success and decrease the need for surgery.
